Current Report Filing (8-k)
January 06 2015 - 8:10AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 31, 2014
Intellect
Neurosciences, Inc.
(Exact Name Of Registrant As Specified In
Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
333-128226 |
|
20-8329066 |
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|
550 Sylvan Ave., Suite 101
Englewood Cliffs, New Jersey |
|
07632 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
(201)
608-5101
(Registrant’s Telephone Number, Including
Area Code)
(Former Name
or Former Address, if Changed Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
| £ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| £ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| £ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| £ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 |
Entry into a Material Definitive Agreement. |
On December 31, 2014, Intellect Neurosciences,
Inc. (the “Company”) and Pfizer Inc. and Rinat Neuroscience Corp. (collectively, “Pfizer”) executed a Settlement
Agreement (the “Settlement Agreement”) to resolve ongoing litigation in connection with In the matter of Intellect
Neurosciences, Inc. v. Pfizer Inc. and Rinat Neuroscience Corp., Supreme Court for the State of New York, County of New York,
Index No. 653320/2012 (the “Action”).
Pursuant to the terms of the
Settlement Agreement, Pfizer agreed to pay the Company $1.2 million to settle the Action and to withdraw the IPR petition with respect to the associated Intellect patent filed by Pfizer with the
USPTO on November 24, 2014. Each of the parties agreed to bear
their own legal costs and attorneys’ fees. The Settlement Agreement constitutes a settlement of the disputed claims and
is not in any way an admission of liability as to any claim, contention or cause of action.
The description of the Settlement Agreement
in this Current Report on Form 8-K does not purport to be complete and shall be provided with the Company’s next periodic
report.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 6, 2015 |
INTELLECT NEUROSCIENCES, INC. |
|
|
|
|
By: |
|
/s/ Elliot Maza |
|
Name: |
Elliot Maza |
|
Title: |
Chief Executive Officer |